# Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

> **NCT03994744** · PHASE2 · UNKNOWN · sponsor: **Hunan Cancer Hospital** · enrollment: 68 (estimated)

## Conditions studied

- Small-cell Lung Cancer
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer Recurrent
- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** PD-1 inhibitor
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03994744
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-20
- **Primary completion:** 2021-08-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994744, "Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03994744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*